Laboratory, Endocrine, & Neurotransmitter Symposium
October 4 - 6, 2019
Earn up to 14.5 CME credits!
Approved for 4.25 Pharm CEs from the OBNM!
Gain additional clinical insight and treatment considerations to evaluate some of the most prevalent and challenging conditions that patients present with, including depression, anxiety, altered mental focus and stamina, sexual dysfunction, sleep disturbances, addictions and dependencies, weight management, and chronic disease. Seating is limited! Register now to reserve your spot today!
Topic: A Spoonful of Sugar: The Impact of Blood Sugar Imbalance on Adrenal and Hormone Health
By: Krista Anderson Ross, ND
October 2, 2019
Join Labrix clinical staff and special guests on the first Wednesday of every month at 9:30 AM and 12:00 PM PST. This free, live webinar series will cover a variety of neuroendocrine topics that will enhance your knowledge, with clinically applicable testing and treatment considerations. 1 CE credit available upon attendee request.
October 12-13, 2019
Labrix will be in Seattle for the WANP conference next month. Come chat with our booth representative and learn more about testing with Doctor's Data and Labrix.
GI Microbial Profiling and Hypertension
By Julia Malkowski, ND, DC | September 18, 2019
Cardiovascular disease and stroke remain leading causes of death in the United States. Hypertension is a contributing factor and the C.D.C. estimates that 33% of adults in the U.S. have hypertension. Treatment approaches including lifestyle interventions and antihypertensives have been the focus to combat hypertension, but is this silent killer influenced by our gastrointestinal (GI) microbiota? Recent scientific discoveries have linked blood pressure and the microbiome in surprising ways that may expand treatment options and improve patient outcomes. Within the microbiome, factors influencing blood pressure include decreased microbial richness and diversity, specific bacterial species and their key metabolites, especially short chain fatty acids.
Blood pressure is a dynamic homeostatic system regulated by various inputs including genetic and environmental influences, endocrine factors, kidney physiology and potentially the GI microbiome. Recent studies have shown that healthy diversity among the primary beneficial bacterial may play a role in regulating blood pressure. A decrease in the beneficial bacteria Butyrivibrio, Clostridium, Faecalibacterium, Enterococcus, Roseburia, Blautia, and Oscillbacter has been associated with hypertension. In contrast, the presence of Prevotella, Klebisella, Porphyromonas, Desulfovibrio and Actinomyces are associated with hypertension. Further, Bacteroides was the most enriched genus in normotensive subjects, while Prevotella was found to be most enriched in hypertensive subjects. Prevotella has been linked to stearic acid, a significant metabolite in the pathogenesis of hypertension which may potentially trigger an inflammatory response.
An inflammatory environment is associated with hypertension. Differences in important metabolites associated with specific bacteria have been reported for hypertensive subjects compared to normotensives. Specific analytes, which may be protective against inflammatory diseases via suppression of cell adhesion molecules in vascular endothelial cells, were shown to be lower in hypertensive subjects. Anti-inflammatory S-carboxymethyl-l-cysteine has also been shown to be decreased in hypertensive subjects. Endogenous N-α-acetyl-l-arginine, stearic acid, phosphatidic acid, and glucoside were significantly increased in hypertensive subjects. Metabolic profiling regarding these metabolites and hypertension has been shown to be closely connected to intestinal microflora.
A decrease in diversity of gastrointestinal microbiota has been associated with hypertension. An increased ratio of Firmicutes/Bacteroidetes has been shown to play a role in the pathogenesis of hypertension and has been shown to be five times higher in hypertensive rats. Pharmacologically induced hypertension in mice was also associated with an increased Firmicutes/Bacteroidetes ratio. Noteworthy, germ free rats developed hypertension after a fecal transplant from hypertensive subjects. Stool concentrations of short chain fatty acids (SCFA), acetate, propionate and butyrate may influence blood pressure as they are vasorelaxant. It has been shown that propionate, can modify renin release and blood pressure. Decreased levels of the SCFA acetate and butyrate have been associated with hypertension.
The microbiome may very well play a role in the pathogenesis of hypertension via microbial richness and diversity, specific bacterial species, certain metabolites, increased Firmicutes/Bacteroidetes ratio and short chain fatty acids. Addressing dysbiosis may prove a helpful adjunctive strategy in combating hypertension. Targeted microbiota profiling and SCFA analysis may aid in treatment options and facilitate monitoring of clinical intervention. With hypertension a contributing factor to cardiovascular disease and stroke, patient outcomes may be improved by the addition of microbial markers and accompanying treatment approaches.
Li, J. et all. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome volume 5, Article number: 14 (2017).
Pevsner-Fischer, M., et all. The gut microbiome and hypertension. Current Opinion in Nephrology and Hypertension: January 2017 - Volume 26 - Issue 1 - p 1–8. doi: 10.1097/MNH.0000000000000293
Pluznicj, J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014 Mar 1; 5(2): 202–207. Published online 2013 Dec 20. doi: 10.4161/gmic.27492